西藏藥業(600211.SH)提示風險:相關疫苗尚處於臨牀前研究階段 存在研發失敗風險
格隆匯 6 月 17日丨西藏藥業(600211.SH)披露風險提示公告,公司近期股價漲幅較大,且股價多次出現漲停,與大盤走勢已嚴重背離。公司強調,公司與斯微生物合作研發相關疫苗項目涉及新冠疫苗、結核疫苗和流感疫苗,僅獲得相關疫苗的商業化權利等,公司不成為相關疫苗的權益所有人。此次合作不會對公司當期經營業績產生重大影響。
另外,相關疫苗尚處於臨牀前研究階段,還需要經過臨牀試驗批准、臨牀I期、II期和/或III期試驗、上市批准、生產設施認證/核查(如適用)等主要環節,方可上市,存在研發失敗的風險。如果研發失敗,已支付給斯微生物的資金、相關臨牀費用存在無法收回的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.